Merus Shares Dip 0.22 as $330M Volume Leaves It 389th in U.S. Listings Amid Biotech Sector Headwinds

Merus (MRUS) closed 0.22% lower on October 10, 2025, with a trading volume of $330 million, ranking 389th among listed stocks. The biotech firm’s shares experienced muted momentum despite a modest increase in liquidity compared to recent sessions. No material corporate updates were disclosed during the reporting period that could directly explain the price movement.

Analysts noted the stock’s performance remained uncorrelated with broader market trends, as sector-specific headwinds in biotechnology R&D funding and regulatory uncertainty persisted. Institutional investor activity showed neutral positioning, with no significant block trades reported. Short interest metrics remained stable, indicating balanced demand-supply dynamics in the near term.

For back-test parameters, the following framework was proposed: The stock universe could include all U.S. listed equities or be narrowed to S&P 500 constituents. Daily rankings might prioritize dollar volume or pure share volume, with entry points defined by next-day open or same-day close. Portfolio construction options included equal weighting or cost-adjusted allocations, while risk controls could involve position limits or cash management rules. Performance evaluation would track cumulative returns, Sharpe ratios, and additional metrics like maximum drawdown upon confirmation.